Safety of sildenafil in premature infants with severe bronchopulmonary dysplasia (SILDI-SAFE): a multicenter, randomized, placebo-controlled, sequential dose-escalating, double-masked, safety study

BACKGROUND: Pulmonary hypertension is a deadly complication of bronchopulmonary dysplasia, the most common pulmonary morbidity of prematurity. Despite these catastrophic consequences, no evidence-based therapies are available for the prevention of pulmonary hypertension in this population. Sildenafi...

Descripción completa

Detalles Bibliográficos
Autores principales: Schneider, Simone, Bailey, Mary, Spears, Tracy, Esther, Charles R., Laughon, Matthew M., Hornik, Christoph P., Jackson, Wesley
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735412/
https://www.ncbi.nlm.nih.gov/pubmed/33317479
http://dx.doi.org/10.1186/s12887-020-02453-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735412/
https://www.ncbi.nlm.nih.gov/pubmed/33317479
http://dx.doi.org/10.1186/s12887-020-02453-7

Ejemplares similares